[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"current-user-roles":3,"user-subscription":3,"bill:119-hr-1117":4},null,{"bill":5,"indexable":129,"summaries":130,"cosponsors":136,"cosponsorSlugs":137,"actions":138,"amendments":157,"amendmentSponsorSlugs":158,"linkages":159,"sponsorSlug":160},{"statusDate":6,"sponsor":7,"updateDate":16,"cboCostEstimates":17,"originChamber":18,"congress":19,"isByRequest":20,"title":21,"createdAt":22,"committeeReports":23,"cosponsorCount":24,"onBehalfOfSponsor":3,"adminOverride":3,"amendmentCount":24,"actionCount":25,"popularTitle":3,"laws":3,"billType":26,"introducedDate":6,"committees":27,"congressGovUrl":28,"constitutionalAuthority":29,"policyArea":30,"deletedAt":3,"latestAction":31,"billNumber":33,"cosponsorCountIncludingWithdrawn":24,"status":34,"shortTitle":21,"officialTitle":35,"keyMilestoneCount":36,"subjects":37,"updatedAt":43,"policyAreaLower":44,"searchTokens":45,"committeeCodes":128},"2025-02-07",{"firstName":8,"lastName":9,"district":10,"fullName":11,"middleName":12,"state":13,"party":14,"bioguideId":15},"Rosa","DeLauro","3","Rep. DeLauro, Rosa L. [D-CT-3]","L.","CT","D","D000216","2026-01-21T03:43:39Z",[],"House",119,false,"Responsibility in Drug Advertising Act of 2025","2026-05-11T15:26:55.141Z",[],0,3,"hr",[],"https:\u002F\u002Fwww.congress.gov\u002Fbill\u002F119th-congress\u002Fhouse-bill\u002F1117","\u003Cpre>\n[Congressional Record Volume 171, Number 26 (Friday, February 7, 2025)]\n[House]\nFrom the Congressional Record Online through the Government Publishing Office [\u003Ca href=\"https:\u002F\u002Fwww.gpo.gov\">www.gpo.gov\u003C\u002Fa>]\nBy Ms. DeLAURO:\nH.R. 1117.\nCongress has the power to enact this legislation pursuant\nto the following:\nArticle 1, Section 8, Clauses 3 and 18 of the United States\nConstitution.\n[Page H585]\n\u003C\u002Fpre>","Health",{"date":6,"text":32},"Referred to the House Committee on Energy and Commerce.",1117,"in_committee","To amend the Federal Food, Drug, and Cosmetic Act to restrict direct-to-consumer drug advertising.",2,[38,39,40,41,42],"Broadcasting, cable, digital technologies","Drug safety, medical device, and laboratory regulation","Internet, web applications, social media","Marketing and advertising","Prescription drugs","2026-05-22T16:47:31.023Z","health",[46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113,114,115,116,117,118,119,120,121,122,123,124,125,126,127],"responsibility","re","res","resp","respo","respon","respons","responsi","responsib","responsibi","responsibil","responsibili","responsibilit","in","drug","dr","dru","advertising","ad","adv","adve","adver","advert","adverti","advertis","advertisi","advertisin","act","of","2025","20","202","to","amend","am","ame","amen","the","federal","fe","fed","fede","feder","federa","food","fo","foo","and","cosmetic","co","cos","cosm","cosme","cosmet","cosmeti","restrict","rest","restr","restri","restric","direct","di","dir","dire","direc","consumer","con","cons","consu","consum","consume","rep","delauro","de","del","dela","delau","delaur","rosa","ro","ros","ct",[],true,[131],{"versionCode":132,"actionDate":6,"actionDesc":133,"text":134,"updateDate":135},"00","Introduced in House","\u003Cp>\u003Cstrong>Responsibility in Drug Advertising Act of 2025\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>This bill prohibits direct-to-consumer advertising of new drugs during the first three years following their approval by the Food and Drug Administration (FDA). Direct-to-consumer advertising includes advertising via social media. \u003C\u002Fp>\u003Cp>Upon request from a drug’s sponsor, the FDA may waive the prohibition during the third year following a drug’s approval if it determines that the direct-to-consumer advertising of the drug would have an affirmative value to public health. Conversely, the FDA may prohibit such advertising beyond the three-year period following approval if it determines that the drug has significant adverse health effects based on post-approval studies, adverse event reports, and other appropriate resources. \u003C\u002Fp>\u003Cp>The prohibition applies to new drugs approved beginning one year before the bill’s enactment.\u003C\u002Fp>","2025-07-23T18:45:01Z",[],{},[139,148,153],{"actionDate":6,"actionDateTime":3,"text":32,"type":140,"actionCode":141,"sourceSystem":142,"committees":144,"recordedVotes":3,"calendarNumber":3,"sequenceIndex":24,"isKeyMilestone":20},"IntroReferral","H11100",{"code":36,"name":143},"House floor actions",[145],{"name":146,"systemCode":147},"Energy and Commerce Committee","hsif00",{"actionDate":6,"actionDateTime":3,"text":133,"type":140,"actionCode":149,"sourceSystem":150,"committees":3,"recordedVotes":3,"calendarNumber":3,"sequenceIndex":36,"isKeyMilestone":129},"1000",{"code":151,"name":152},9,"Library of Congress",{"actionDate":6,"actionDateTime":3,"text":133,"type":140,"actionCode":154,"sourceSystem":155,"committees":3,"recordedVotes":3,"calendarNumber":3,"sequenceIndex":156,"isKeyMilestone":129},"Intro-H",{"code":151,"name":152},1,[],{},[],"rosa-l-delauro"]